COA Conference Coverage
Featured Articles
(AJMC Managed Markets Network) Apr 5, 2019 - The first day of the 2019 Community Oncology Conference, the major annual meeting of the Community Oncology Alliance (COA), featured an update on its effort to find alternatives to CMS' Oncology Care Model. After a year in development, the Community Oncology Alliance (COA) will file its...
Read Article
Latest Articles
April 08, 2019
April 05, 2019

OBR Tweets

May 30
Pfizer Shares Fall After-Hours After Suspension Of Cancer Study #ASCO20 https://t.co/kkMwIf4371

May 30
Genentech: FDA Approves Tecentriq in Combination With Avastin for Some Liver Cancer Patients #ASCO20 https://t.co/PZv8m8CUvk

May 30
Katie Kelley, MD, of @UCSF discusses fitting tremelimumab + durvalumab into HCC treatment algorithms #ASCO20 https://t.co/PgkmKoeVoz

May 30
Nicholas Vogelzang, MD, FAC, FASCO, of @CCCNevada explains how cabazitaxel should be used in various lines of treat… https://t.co/WAkWkUFmEf

May 30
Vivek Subbiah @VivekSubbiah , MD, of @MDAndersonNews on the FDA approved product, selpercatanib, for RET-driven lu… https://t.co/ILwAZtxXfh

May 30
Final Prosper Results Show Xtandi® (Enzalutamide) Significantly Extends Overall Survival In Men With Non-Metastatic… https://t.co/BobQ15CZOj

May 30
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Nec… https://t.co/UKu93KJpLA

May 30
Vivek Subbiah @VivekSubbiah , MD, @MDAndersonNews describes solid tumor tests for RET fusion and similarities it m… https://t.co/9MlHzs422k

May 30
Saad Usmani @szusmani, MD, of @LevineCancer outlines the Phase 1 study investigating teclistamab in relapsed/refrac… https://t.co/ODs1HrnftW

May 30
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early… https://t.co/LM1kg7cgcx